MD20140107A2 - Anticorpi împotriva metaloproteinazei 9 din matrice - Google Patents

Anticorpi împotriva metaloproteinazei 9 din matrice Download PDF

Info

Publication number
MD20140107A2
MD20140107A2 MDA20140107A MD20140107A MD20140107A2 MD 20140107 A2 MD20140107 A2 MD 20140107A2 MD A20140107 A MDA20140107 A MD A20140107A MD 20140107 A MD20140107 A MD 20140107A MD 20140107 A2 MD20140107 A2 MD 20140107A2
Authority
MD
Moldova
Prior art keywords
antibodies
matrix metalloproteinase
mmp9
functional fragment
binding proteins
Prior art date
Application number
MDA20140107A
Other languages
English (en)
Russian (ru)
Inventor
Виктория СМИТ
Скотт МакКОЛИ
Original Assignee
Gilead Biologics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Biologics, Inc. filed Critical Gilead Biologics, Inc.
Publication of MD20140107A2 publication Critical patent/MD20140107A2/ro

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • C12N9/6491—Matrix metalloproteases [MMP's], e.g. interstitial collagenase (3.4.24.7); Stromelysins (3.4.24.17; 3.2.1.22); Matrilysin (3.4.24.23)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24035—Gelatinase B (3.4.24.35), i.e. matrix metalloprotease 9 or MMP9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96486—Metalloendopeptidases (3.4.24)
    • G01N2333/96491—Metalloendopeptidases (3.4.24) with definite EC number
    • G01N2333/96494—Matrix metalloproteases, e. g. 3.4.24.7

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Invenţia se referă la imunologie, în special la compoziţii şi metode de utilizare a lor, care implică proteine de legare, de exemplu anticorpi şi fragmente de legare a antigenului acestora, care se leagă de metaloproteinaza matriceală-9 (MMP9) (MMP9 este cunoscută şi ca gelatinaza-B), cum ar fi în cazul în care proteinele de legare cuprind un lanţ imunoglobulinic greu (Ig) (fragmentul funcţional al acestuia) şi un lanţ uşor Ig (fragmentul funcţional al acestuia).
MDA20140107A 2012-02-29 2012-02-29 Anticorpi împotriva metaloproteinazei 9 din matrice MD20140107A2 (ro)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2012/027160 WO2013130078A1 (en) 2012-02-29 2012-02-29 Antibodies to matrix metalloproteinase 9

Publications (1)

Publication Number Publication Date
MD20140107A2 true MD20140107A2 (ro) 2015-03-31

Family

ID=45816000

Family Applications (1)

Application Number Title Priority Date Filing Date
MDA20140107A MD20140107A2 (ro) 2012-02-29 2012-02-29 Anticorpi împotriva metaloproteinazei 9 din matrice

Country Status (23)

Country Link
US (4) US9550836B2 (ro)
EP (1) EP2820048B1 (ro)
JP (1) JP6067756B2 (ro)
KR (1) KR20140130724A (ro)
CN (1) CN104395345A (ro)
AP (1) AP2014007907A0 (ro)
AU (4) AU2012318302C1 (ro)
BR (1) BR112014021477A2 (ro)
CA (1) CA2865530C (ro)
CL (1) CL2014002282A1 (ro)
CO (1) CO7061040A2 (ro)
CR (1) CR20140443A (ro)
EA (1) EA201491575A1 (ro)
EC (1) ECSP14020504A (ro)
ES (1) ES2731441T3 (ro)
HK (1) HK1208036A1 (ro)
IN (1) IN2014DN08011A (ro)
MD (1) MD20140107A2 (ro)
MX (1) MX2014010449A (ro)
PH (1) PH12014501931A1 (ro)
SG (1) SG11201405305PA (ro)
WO (1) WO2013130078A1 (ro)
ZA (1) ZA201406319B (ro)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101827048B1 (ko) 2010-08-27 2018-02-07 길리아드 바이오로직스, 인크. 매트릭스 메탈로프로테이나제 ９에 대한 항체
NZ629178A (en) 2012-02-29 2016-09-30 Gilead Biologics Inc Antibodies to matrix metalloproteinase 9
US9550836B2 (en) 2012-02-29 2017-01-24 Gilead Biologics, Inc. Method of detecting human matrix metalloproteinase 9 using antibodies
EP3110847A1 (en) * 2014-02-27 2017-01-04 Gilead Sciences, Inc. Antibodies to matrix metalloproteinase 9 and methods of use thereof
EP2985296A1 (en) 2014-08-13 2016-02-17 Calypso Biotech SA Antibodies specific for MMP9
EP2985295A1 (en) * 2014-08-13 2016-02-17 Calypso Biotech SA Antibodies specific for MMP9
CN105037553B (zh) * 2015-08-20 2018-04-17 内蒙古蒙元生物基因科技有限公司 一种能够检测癌症的免疫球蛋白
CA3019003A1 (en) 2016-04-08 2017-10-12 Gilead Sciences, Inc. Compositions and methods for treating cancer, inflammatory diseases and autoimmune diseases
US10326830B1 (en) * 2016-09-02 2019-06-18 Amazon Technologies, Inc. Multipath tunneling to a service offered at several datacenters
BR112019012253A2 (pt) 2016-12-16 2020-01-28 Centre Hospitalier Univ Bordeaux inibidores de mmp9 e usos dos mesmos na prevenção ou tratamento de um transtorno de despigmentação
US10941178B2 (en) 2017-03-17 2021-03-09 Gilead Sciences, Inc. Method of purifying an antibody
JP7109440B2 (ja) 2017-07-18 2022-07-29 第一三共株式会社 活性型ｍｍｐ－９結合ペプチド
CN110885375B (zh) * 2019-12-20 2021-07-02 南京融捷康生物科技有限公司 特异性针对mmp-9蛋白锌离子结合结构域的单域抗体及产品与应用
CN111785321B (zh) * 2020-06-12 2022-04-05 浙江工业大学 一种基于深度卷积神经网络的dna绑定残基预测方法
CN117327186B (zh) * 2023-07-12 2024-03-12 北京达成生物科技有限公司 结合mmp3蛋白的双特异性抗体及其用途
WO2025076280A1 (en) 2023-10-05 2025-04-10 Ashibio, Inc. Methods and compositions for treating mmp-9 mediated disorders

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
ES2108048T3 (es) 1990-08-29 1997-12-16 Genpharm Int Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos.
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
GB9022788D0 (en) 1990-10-19 1990-12-05 Cortecs Ltd Pharmaceutical formulations
JPH07501451A (ja) 1991-11-25 1995-02-16 エンゾン・インコーポレイテッド 多価抗原結合タンパク質
CA2379373A1 (en) * 1999-07-13 2001-01-18 University Of Southern California Novel method and composition for inhibition of angiogenesis using antagonists based on mmp-9 and .beta.1 integrins
CN1459505A (zh) * 2002-05-21 2003-12-03 赵平 中国汉族人基质金属蛋白酶－9基因重构、表达、纯化及其医学应用
AU2003270330B2 (en) * 2002-09-06 2009-07-30 Alexion Pharmaceuticals, Inc. Method of treatment of asthma using antibodies to complement component C5
EP1957540B1 (en) * 2005-12-02 2012-06-13 Genentech, Inc. Binding polypeptides and uses thereof
PE20090765A1 (es) * 2007-06-08 2009-07-10 Irm Llc Metodos y composiciones para inducir la apoptosis en celulas cancerosas
JP2011517320A (ja) * 2008-03-03 2011-06-02 ダイアックス コーポレーション メタロプロテアーゼ９結合タンパク質およびメタロプロテアーゼ２結合タンパク質
WO2009111450A2 (en) * 2008-03-03 2009-09-11 Dyax Corp. Metalloproteinase 9 binding proteins
US20110262396A1 (en) * 2008-10-22 2011-10-27 Dyax Corp. Combination treatments comprising protease binding proteins for inflammatory disorders
WO2010059543A1 (en) * 2008-11-20 2010-05-27 Merck Sharp & Dohme Corp. Generation and characterization of anti-notch antibodies for therapeutic and diagnostic use
EA201270701A1 (ru) * 2010-01-27 2013-01-30 Йеда Рисеч Энд Девелопмент Ко. Лтд. Ингибирующие металлопротеины антитела
KR101827048B1 (ko) * 2010-08-27 2018-02-07 길리아드 바이오로직스, 인크. 매트릭스 메탈로프로테이나제 ９에 대한 항체
US9550836B2 (en) 2012-02-29 2017-01-24 Gilead Biologics, Inc. Method of detecting human matrix metalloproteinase 9 using antibodies
NZ629178A (en) 2012-02-29 2016-09-30 Gilead Biologics Inc Antibodies to matrix metalloproteinase 9

Also Published As

Publication number Publication date
BR112014021477A2 (pt) 2018-06-12
SG11201405305PA (en) 2014-09-26
CR20140443A (es) 2014-11-17
CN104395345A (zh) 2015-03-04
JP6067756B2 (ja) 2017-01-25
AU2012318302C1 (en) 2017-06-15
HK1205153A1 (en) 2015-12-11
ZA201406319B (en) 2016-02-24
AU2017216508A1 (en) 2017-08-31
MX2014010449A (es) 2015-02-10
AU2017216508B2 (en) 2019-03-07
CO7061040A2 (es) 2014-09-19
EP2820048A1 (en) 2015-01-07
ECSP14020504A (es) 2015-09-30
EP2820048B1 (en) 2019-04-17
US9550836B2 (en) 2017-01-24
WO2013130078A1 (en) 2013-09-06
KR20140130724A (ko) 2014-11-11
JP2015514394A (ja) 2015-05-21
US20170183421A1 (en) 2017-06-29
AU2015242967B2 (en) 2017-08-24
HK1208036A1 (en) 2016-02-19
AU2015242967A1 (en) 2015-11-05
US20190127486A1 (en) 2019-05-02
US11634505B2 (en) 2023-04-25
PH12014501931A1 (en) 2014-11-24
CA2865530C (en) 2019-02-19
AU2017261626A1 (en) 2017-12-07
EA201491575A1 (ru) 2015-01-30
US10800857B2 (en) 2020-10-13
US20210054101A1 (en) 2021-02-25
US20150140580A1 (en) 2015-05-21
IN2014DN08011A (ro) 2015-05-01
AU2012318302A1 (en) 2013-09-19
AU2012318302B2 (en) 2016-08-18
AP2014007907A0 (en) 2014-08-31
ES2731441T3 (es) 2019-11-15
CL2014002282A1 (es) 2015-02-20
NZ629888A (en) 2017-02-24
CA2865530A1 (en) 2013-09-06

Similar Documents

Publication Publication Date Title
MD20140108A2 (ro) Anticorpi împotriva metaloproteinazei 9 matriciale
MD20140107A2 (ro) Anticorpi împotriva metaloproteinazei 9 din matrice
PH12016501691A1 (en) Antibodies to matrix metalloproteinase 9
EA201591153A1 (ru) Антитела, связывающиеся с tl1a, и их применение
PH12018502225A1 (en) Anti-il-33 antibodies, compositions, methods and uses thereof
MX382398B (es) Proteinas de union a antigeno st2.
MX2011011754A (es) Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c3b.
EA201491214A1 (ru) Композиции и способы применения антител, нацеленных на фактор p
JOP20160131B1 (ar) الأجسام المضادة للعامل xi وطرق الاستخدام
EA201591091A1 (ru) Антигенсвязывающие белки для bcma
AR105267A1 (es) Anticuerpos de unión a tau
MX2015005719A (es) Terapias de combinacion que usan moleculas de union anti-psl y pcrv de pseudomonas.
EA201291065A1 (ru) Антитела против vla-4
EA201590918A1 (ru) Антитела к bmp-6
EA201990895A1 (ru) Антитела к о1 и варианты их применения
MX2016011177A (es) Anticuerpos a la metaloproteinasa de matriz 9 y metodos de uso de los mismos.
TH148296A (th) แอนติบอดีต้านเมทริกซ์เมทัลโลโปรตีเนส 9 (Antibodies to matrix metalloproteinase 9)
CL2010000521A1 (es) Anticuerpo aislado o fragmento que bloquea la fijacion de la union de la proteina wise; secuencias de cdr de la cadena liviana y pesada; polipeptido inmunogenico de wise; composicion farmaceutica que comprende dicho anticuerpo.

Legal Events

Date Code Title Description
FA9A Abandonment or withdrawal of application (patent for invention)